Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study

Cancer

Volumn 123, Issue , 2017, Pages 5160-5177

  Steele, C Brooke ^a   Li, Jun ^a   Huang, Bin ^b   Weir, Hannah K ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

Author keywords

and End Results (SEER) summary stage; cancer registries; early detection of cancer; Epidemiology; population based survival; prevention and control; prostate cancer; Surveillance; therapeutics; trends

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLACK PERSON; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; FOLLOW UP; HEALTH INSURANCE; HEALTH LITERACY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; AFRICAN AMERICAN; EPIDEMIOLOGY; ETHNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; REGISTER; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGISTRIES; UNITED STATES; YOUNG ADULT;

EID: 85037660331     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31026     Document Type: Article

References (62)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. US Cancer Statistics (USCS) Working Group. US Cancer Statistics: 1999-2013 Incidence and Mortality Web-Based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control, Prevention and National Cancer Institute; 2016. Available at: www.cdc.gov/uscs. Accessed April 1, 2016.
3. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337.
4. National Cancer Institute. Prostate specific antigen (PSA) test. Bethesda, MD: National Cancer Institute; 2016. Available at: http://www.cancer.gov/types/prostate/psa-fact-sheet. Accessed March 31, 2016.
5. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer—Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
6. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2016. Available at: http://seer.cancer.gov/csr/1975_2013/ (http://seer.cancer.gov/csr/1975_2013), based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Accessed April 1, 2016.
7. Coleman MP, Quaresma M, Berrino F, et al. CONCORD Working Group. Cancer survival in 5 continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9:730-756.
8. Allemani C, Harewood R, Johnson CJ, et al. Population-based cancer survival in the United States: data, quality control, and statistical methods. Cancer. 2017;123:4982-4993.
9. Fritz AG, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
10. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA, eds. SEER Summary Staging Manual-2000: Codes and Coding Instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute; 2001.
11. Surveillance Epidemiology and End Results (SEER) Program. Collaborative Stage. Bethesda, MD: National Cancer Institute; 2004. Available at: http://seer.cancer.gov/tools/collabstaging/. Accessed April 1, 2016.
12. Pohar Perme M, Stare J, Esteve J. On estimation in relative survival. Biometrics. 2012;68:113-120.
13. Rachet B, Maringe C, Woods LM, Ellis L, Spika D, Allemani C. Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations [serial online]. BMC Public Health. 2015;15:1240.
14. Spika D, Bannon F, Bonaventure A, et al. Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods [serial online]. BMC Cancer. 2017;17:159.
15. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307-2316.
16. Quaresma M, Coleman MP, Rachet B. Funnel plots for population-based cancer survival: principles, methods and applications. Stat Med. 2014;33:1070-1080.
17. Hoffman RM, Meisner AL, Arap W, et al. Trends in United States prostate cancer incidence rates by age and stage, 1995-2012. Cancer Epidemiol Biomarkers Prev. 2015;25:259-263.
18. Singh SD, Henley SJ, Ryerson AB. Summary of notifiable noninfectious conditions and disease outbreaks—United States, 2011. MMWR Morb Mortal Wkly Rep. 2015;62:11-51.
19. Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2015;138:1388-1400.
20. Etzioni R, Gulati R. Recent trends in PSA testing and prostate cancer incidence: a look at context. JAMA. 2015;314:2054-2061.
21. Collin SM, Martin RM, Metcalfe C, et al. Prostate cancer mortality in the USA and UK in 1975-2004. Lancet Oncol. 2008;9:445-452.
22. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;45:152-156.
23. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16-27.
24. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers. JAMA Oncol. 2015;1:88-96.
25. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities. CA Cancer J Clin. 2011;61:212-236.
26. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290-308.
27. Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) registries. J Natl Cancer Inst Monogr. 2014;49:236-243.
28. Brooks GA, Li L, Sharma DB, et al. Regional variation in spending and survival for older adults with cancer. J Natl Cancer Inst. 2013;105:634-642.
29. Niu X, Roche LM, Pawlish KS, Henry KA. Cancer survival disparities by health insurance status. Cancer Med. 2013;2:403-411.
30. Loeb S, Bjurlin M, Tammela TL, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046-1055.
31. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
32. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
33. Livingston CJ, Freeman RJ, Mohammad A, et al. Choosing Wisely in preventive medicine: the American College of Preventive Medicine's top 5 list recommendations. Am J Prev Med. 2016;51:141-149.
34. American Academy of Family Physicians. Prostate Cancer: Clinical Preventive Services Recommendation. 2012. Leawood, KS: American Academy of Family Physicians; 2012. Available at: http://www.aafp.org/patient-care/clinical-recommendations/all/prostate-cancer.html. Accessed April 1, 2016.
35. American Urological Association (AUA). Early Detection of Prostate Cancer: AUA Guideline, 2013. Seaford, NY: AUA; 2013. Available at: https://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm. Accessed April 1, 2016.
36. Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:718-725.
37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection, Version 2.2016. Fort Washington, PA: NCCN; 2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed April 1, 2016.
38. Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening—a perspective on the current state of the evidence. N Engl J Med. 2017;376:1285-1289.
39. Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate cancer screening practices and prostate cancer epidemiology [published online ahead of print May 25, 2017]. J Urol. doi: 10.1016/j/juro.2017.05.074.
40. Rodgers L, Peer CJ, Figg WD. Diagnosis, staging, and risk stratification in prostate cancer: utilizing diagnostic tools to avoid unnecessary therapies and side effects [published online ahead of print May 5, 2017]. Cancer Biol Ther. doi: 10.1080/15384047.2017.1323600.
41. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-5963.
42. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;1123:592-599.
43. Schroder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
44. Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118:4280-4289.
45. Nezolosky MD, Dinh KT, Muralidhar V, et al. Significant increase in prostatectomy and decrease radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016;34:57.e15-57.e22.
46. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80-82.
47. Weiner AB, Patel SG, Etzioni R, Eggener SE. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2014;193:95-102.
48. Schmid M, Meyer CP, Reznor G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol. 2016;2:85-93.
49. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010;28:1069-1074.
50. Chornokur Dalton K, Borysova ME, Kumar NB. Disparities at prevention, diagnosis, treatment, and survival in African American men affected by prostate cancer. Prostate. 2011;71:985-997.
51. Underwood W 3rd, Jackson J, Wei JT, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer. 2005;103:538-545.
52. Cary KC, Punnen S, Odisho AY, et al. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America. Prostate Cancer Prostatic Dis. 2015;18:149-154.
53. Xu J, Janisse J, Ruterbusch J, Ager J, Schwartz KL. Racial differences in treatment decision-making for men with clinically localized prostate cancer: a population-based study. J Racial Ethn Health Disparities. 2016;3:35-45.
54. Presley CJ, Raldow AC, Cramer LD, et al. A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol. 2013;4:1-8.
55. Steenland K, Goodman M, Liff J, et al. The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology. 2011;77:581-587.
56. Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. J Gen Intern Med. 2003;18:845-853.
57. Denberg TD, Beaty BL, Kim FJ, Steiner JF. Marriage and ethnicity predict treatment in localized prostate carcinoma. Cancer. 2005;103:1819-1825.
58. Hoffman RM, Van Den Eeden SK, Davis KM, et al. Decision-making processes among men with low-risk prostate cancer: a survey study [published online ahead of print June 13, 2017]. Psychooncology. doi: 10.1002/pon.4469.
59. Brawley OW. Some thoughts on health surveillance data, race, and population categorization. CA Cancer J Clin. 2016 May;66:179-181.
60. White MC, Babcock F, Hayes NS, et al. The history and use of cancer registry data by public health cancer control programs in the United States. Cancer. 2017;123:4969-4976.
61. Hall IJ, Lee Smith J. Evolution of a CDC public health research agenda for low-risk prostate cancer. Am J Prev Med. 2015;49(6 suppl 5):S483-S488.
62. Johnson CJ, Weir HK, Fink AK, et al. Accuracy of Cancer Mortality Study Group. The impact of National Death Index linkages on population-based cancer survival rates in the United States. Cancer Epidemiol. 2013;37:20-28.